Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.71
ARAY's Cash to Debt is ranked lower than
69% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ARAY: 0.71 )
Ranked among companies with meaningful Cash to Debt only.
ARAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.71  Med: 9999.00 Max: No Debt
Current: 0.71
Equity to Asset 0.06
ARAY's Equity to Asset is ranked lower than
93% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ARAY: 0.06 )
Ranked among companies with meaningful Equity to Asset only.
ARAY' s Equity to Asset Range Over the Past 10 Years
Min: -0.65  Med: 0.40 Max: 0.69
Current: 0.06
-0.65
0.69
Interest Coverage N/A
ARAY's Interest Coverage is ranked higher than
79% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 45.13 vs. ARAY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARAY' s Interest Coverage Range Over the Past 10 Years
Min: 88.63  Med: 9999.00 Max: N/A
Current: N/A
F-Score: 4
Z-Score: 0.20
M-Score: -0.87
WACC vs ROIC
8.36%
-5.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.84
ARAY's Operating margin (%) is ranked lower than
55% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. ARAY: -0.84 )
Ranked among companies with meaningful Operating margin (%) only.
ARAY' s Operating margin (%) Range Over the Past 10 Years
Min: -63.32  Med: -5.57 Max: 1.28
Current: -0.84
-63.32
1.28
Net-margin (%) -5.89
ARAY's Net-margin (%) is ranked lower than
60% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ARAY: -5.89 )
Ranked among companies with meaningful Net-margin (%) only.
ARAY' s Net-margin (%) Range Over the Past 10 Years
Min: -63.7  Med: -10.10 Max: 2.56
Current: -5.89
-63.7
2.56
ROE (%) -35.18
ARAY's ROE (%) is ranked lower than
74% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. ARAY: -35.18 )
Ranked among companies with meaningful ROE (%) only.
ARAY' s ROE (%) Range Over the Past 10 Years
Min: -68.25  Med: -25.19 Max: 4.2
Current: -35.18
-68.25
4.2
ROA (%) -4.19
ARAY's ROA (%) is ranked lower than
56% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. ARAY: -4.19 )
Ranked among companies with meaningful ROA (%) only.
ARAY' s ROA (%) Range Over the Past 10 Years
Min: -29.89  Med: -7.36 Max: 1.72
Current: -4.19
-29.89
1.72
ROC (Joel Greenblatt) (%) -5.34
ARAY's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. ARAY: -5.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -214.23  Med: -38.61 Max: 33.63
Current: -5.34
-214.23
33.63
Revenue Growth (3Y)(%) -5.60
ARAY's Revenue Growth (3Y)(%) is ranked lower than
73% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. ARAY: -5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.9  Med: 6.40 Max: 134.9
Current: -5.6
-6.9
134.9
EPS Growth (3Y)(%) -20.50
ARAY's EPS Growth (3Y)(%) is ranked lower than
79% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. ARAY: -20.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.5  Med: 11.30 Max: 91.3
Current: -20.5
-20.5
91.3
» ARAY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ARAY Guru Trades in Q2 2015

Paul Tudor Jones 44,869 sh (New)
Jim Simons 1,130,652 sh (+152.55%)
PRIMECAP Management 8,603,700 sh (+1.27%)
Steven Cohen Sold Out
Chuck Royce 1,997,500 sh (-2.39%)
» More
Q3 2015

ARAY Guru Trades in Q3 2015

Steven Cohen 1,581,300 sh (New)
Jim Simons 1,996,723 sh (+76.60%)
Chuck Royce 2,153,500 sh (+7.81%)
PRIMECAP Management 8,603,700 sh (unchged)
Paul Tudor Jones 14,531 sh (-67.61%)
» More
Q4 2015

ARAY Guru Trades in Q4 2015

Steven Cohen 1,893,000 sh (+19.71%)
Paul Tudor Jones 17,001 sh (+17.00%)
Jim Simons 2,275,523 sh (+13.96%)
PRIMECAP Management 8,603,700 sh (unchged)
Chuck Royce 1,734,900 sh (-19.44%)
» More
Q1 2016

ARAY Guru Trades in Q1 2016

Jim Simons 2,781,400 sh (+22.23%)
Chuck Royce 1,999,500 sh (+15.25%)
Paul Tudor Jones Sold Out
PRIMECAP Management 8,544,500 sh (-0.69%)
Steven Cohen 1,640,800 sh (-13.32%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:PMTHF, NYSE:CRY, NYSE:IVC, OTCPK:MZRTF, NAS:XENT, NAS:EXAC, OTCPK:NMRD, NAS:GNMK, NAS:HTWR, OTCPK:IPDQF, NAS:ELOS, OTCPK:JIDG, NAS:CSII, NAS:IRMD, NAS:TNDM, NAS:RTIX, OTCPK:VICA, NAS:KTWO, NAS:AXGN, OTCPK:DMTRF » details
Traded in other countries:XEJ.Germany,
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. It develops, manufactures, sells and supports precise treatment solutions. The Company's technologies are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy and image guided radiation therapy and adaptive radiation therapy. It operates in Europe, Middle East, India and Africa, Asia Pacific and Japan. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws. Its competitors are Elekta AB and Varian Medical Systems, Inc, Mitsubishi Heavy Industries, BrainLAB AG, and ViewRay Inc.

Ratios

vs
industry
vs
history
P/B 6.51
ARAY's P/B is ranked lower than
82% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ARAY: 6.51 )
Ranked among companies with meaningful P/B only.
ARAY' s P/B Range Over the Past 10 Years
Min: 1.1  Med: 3.27 Max: 11.51
Current: 6.51
1.1
11.51
P/S 0.99
ARAY's P/S is ranked higher than
78% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. ARAY: 0.99 )
Ranked among companies with meaningful P/S only.
ARAY' s P/S Range Over the Past 10 Years
Min: 0.8  Med: 1.60 Max: 6
Current: 0.99
0.8
6
EV-to-EBITDA 31.42
ARAY's EV-to-EBITDA is ranked lower than
78% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. ARAY: 31.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -666.8  Med: 25.30 Max: 1904.7
Current: 31.42
-666.8
1904.7
Current Ratio 1.66
ARAY's Current Ratio is ranked lower than
76% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. ARAY: 1.66 )
Ranked among companies with meaningful Current Ratio only.
ARAY' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.93 Max: 3.13
Current: 1.66
0.92
3.13
Quick Ratio 1.15
ARAY's Quick Ratio is ranked lower than
76% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ARAY: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
ARAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.48 Max: 2.67
Current: 1.15
0.72
2.67
Days Inventory 167.23
ARAY's Days Inventory is ranked lower than
63% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. ARAY: 167.23 )
Ranked among companies with meaningful Days Inventory only.
ARAY' s Days Inventory Range Over the Past 10 Years
Min: 70.63  Med: 114.91 Max: 199.92
Current: 167.23
70.63
199.92
Days Sales Outstanding 80.38
ARAY's Days Sales Outstanding is ranked lower than
61% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. ARAY: 80.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.26  Med: 63.29 Max: 101.57
Current: 80.38
26.26
101.57
Days Payable 32.55
ARAY's Days Payable is ranked lower than
79% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. ARAY: 32.55 )
Ranked among companies with meaningful Days Payable only.
ARAY' s Days Payable Range Over the Past 10 Years
Min: 20.39  Med: 38.88 Max: 122.61
Current: 32.55
20.39
122.61

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.62
ARAY's Price/Median PS Value is ranked higher than
83% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ARAY: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
ARAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.02 Max: 3.22
Current: 0.62
0.52
3.22
Earnings Yield (Greenblatt) (%) -0.68
ARAY's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ARAY: -0.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.7  Med: 0.80 Max: 2.9
Current: -0.68
-0.7
2.9

More Statistics

Revenue (TTM) (Mil) $405.6
EPS (TTM) $ -0.30
Beta1.43
Short Percentage of Float15.32%
52-Week Range $4.80 - 7.54
Shares Outstanding (Mil)80.92

Analyst Estimate

Jun16 Jun17
Revenue (Mil $) 403 435
EPS ($) -0.30 -0.08
EPS w/o NRI ($) -0.30 -0.08
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
Accuray Inc. (ARAY) President & CEO Euan Thomson sells 12,500 Shares Mar 11 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 1,000 Shares Mar 07 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 9,000 Shares Mar 02 2011 

More From Other Websites
Accuray Receives 510(k) FDA Clearance for the Radixact™ Image-Guided Radiation Therapy Platform... Jun 27 2016
6:31 am Accuray receives 510(k) clearance from the FDA for the Radixact Treatment Delivery Platform,... Jun 27 2016
Accuray Receives 510(k) FDA Clearance for the Radixact™ Image-Guided Radiation Therapy Platform... Jun 27 2016
Accuray's (ARAY) TomoTherapy System Uptake on the Rise Jun 24 2016
FUCAM Treats 1,000 Breast Cancer Patients with the TomoTherapy® System Jun 21 2016
FUCAM Treats 1,000 Breast Cancer Patients with the TomoTherapy® System Jun 21 2016
Accuray Wins 7 TomoTherapy Orders from NHS, Stock Up Jun 17 2016
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems Jun 16 2016
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems Jun 16 2016
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems Jun 16 2016
Accuray, Inc. breached its 50 day moving average in a Bearish Manner : ARAY-US : June 13, 2016 Jun 13 2016
Zeltiq Aesthetics Extends 3-Day Rally to 4 Jun 06 2016
ETF’s with exposure to Accuray, Inc. : May 26, 2016 May 26 2016
Accuray to Participate in the 2016 Jefferies Healthcare Conference May 25 2016
Accuray to Participate in the 2016 Jefferies Healthcare Conference May 25 2016
ACCURAY INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 24 2016
Accuray to Host Analyst and Investor Day on May 20, 2016 May 19 2016
Accuray to Host Analyst and Investor Day on May 20, 2016 May 19 2016
ACCURAY INC Financials May 06 2016
Accuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric... May 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)